Niemeyer C M, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, Haas O, Harbott J, Hasle H, Kerndrup G, Locatelli F, Mann G, Stollmann-Gibbels B, van't Veer-Korthof E T, van Wering E, Zimmermann M
Department of Pediatrics, University of Freiburg, Germany.
Blood. 1997 May 15;89(10):3534-43.
Chronic myelomonocytic leukemia (CMML) is a rare hematopoietic malignancy of childhood. To define the clinical and hematologic characteristics of the disease, we performed a retrospective analysis of 110 children given the diagnosis CMML irrespective of karyotype. Median age at diagnosis was 1.8 years. Neurofibromatosis type 1 was known in 14% and other clinical abnormalities in 7% of the children. At presentation, the medium white blood count was 35 x 10(9)/L, with a median monocyte count of 7 x 10(9)/L. Karyotypic abnormalities in bone marrow cells were noted in 36% of the patients, whereas 26% of the children had monosomy 7. Children with monosomy 7 did not differ from those with normal karyotype with respect to their clinical presentation. However, they did display some characteristic hematologic features. Of 110 children, 38 received an allogeneic bone marrow transplant (BMT). The probability of survival at 10 years was 0.39 (standard error [SE] = 0.10) for the BMT group and 0.06 (SE = 0.4) for the 72 patients of the non-BMT group. Platelet count, age, and hemoglobin F at diagnosis were the main predicting factors for the length of survival in the non-BMT group. There is a strong need for a broad agreement on nomenclature in children with myelodysplastic syndromes (MDS). We propose here to use the French-American-British classification for MDS in childhood.
慢性粒单核细胞白血病(CMML)是一种罕见的儿童造血系统恶性肿瘤。为明确该疾病的临床和血液学特征,我们对110例确诊为CMML的儿童进行了回顾性分析,无论其核型如何。诊断时的中位年龄为1.8岁。14%的儿童患有1型神经纤维瘤病,7%的儿童有其他临床异常。就诊时,中位白细胞计数为35×10⁹/L,中位单核细胞计数为7×10⁹/L。36%的患者骨髓细胞存在核型异常,26%的儿童有7号染色体单体。7号染色体单体的儿童与核型正常的儿童在临床表现上无差异。然而,他们确实表现出一些特征性的血液学特征。110例儿童中,38例接受了异基因骨髓移植(BMT)。BMT组10年生存率为0.39(标准误[SE]=0.10),非BMT组72例患者的10年生存率为0.06(SE=0.4)。诊断时的血小板计数、年龄和血红蛋白F是非BMT组生存时间的主要预测因素。对于骨髓增生异常综合征(MDS)患儿的命名,迫切需要达成广泛共识。我们在此提议采用法国-美国-英国(FAB)儿童MDS分类法。